US 12,084,471 B2
Amino acid derivative of glucosamine stimulating extracellular matrix synthesis and pharmaceutical composition comprising the same
Filippo Surace, Otranto (IT); and Roberto Scandurra, Rome (IT)
Assigned to CARTILAGO S.R.L., Maglie (IT)
Filed by CARTILAGO S.R.L., Maglie (IT)
Filed on May 22, 2023, as Appl. No. 18/321,363.
Application 18/321,363 is a continuation of application No. 17/277,876, granted, now 11,685,760, previously published as PCT/IB2019/057896, filed on Sep. 19, 2019.
Claims priority of application No. 102018000008758 (IT), filed on Sep. 20, 2018.
Prior Publication US 2023/0399353 A1, Dec. 14, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 31/7008 (2006.01); C07H 15/207 (2006.01)
CPC C07H 15/207 (2013.01) [A61K 9/00 (2013.01); A61K 9/0019 (2013.01); A61K 9/06 (2013.01); A61K 31/7008 (2013.01)] 19 Claims
 
1. An injectable solution pharmaceutical composition comprising an amino acid derivative of glucosamine having the following Formula 1 of general structure:

OG Complex Work Unit Chemistry
or the pharmaceutically acceptable salt, solvate, hydrate or stereoisomer thereof, wherein the group R represents an amino acid, an N-acyl derivative of an amino acid or an N-acyl derivative of a peptide and wherein the amine group of glucosamine is bound by amide bond to the carboxyl side chain of said amino acid; wherein the pharmaceutical composition comprises the amino acid derivative of glucosamine at a concentration of between 0.5% by weight and 4.5% by weight, together with carriers suitable for injection.